These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Young E; Wells P; Holloway S; Weitz J; Hirsh J Thromb Haemost; 1994 Mar; 71(3):300-4. PubMed ID: 8029793 [TBL] [Abstract][Full Text] [Related]
7. [Low molecular weight heparins in everyday practice]. Horellou MH; Samama M J Mal Vasc; 1991; 16(2):179-83. PubMed ID: 1650391 [TBL] [Abstract][Full Text] [Related]
8. An overview of clinical trials of low molecular weight heparin fractions. Levine MN; Hirsh J Acta Chir Scand Suppl; 1988; 543():73-9. PubMed ID: 2847461 [TBL] [Abstract][Full Text] [Related]
9. The relationship between ex vivo anti-factor Xa levels and efficacy/safety of low molecular weight heparin. Turpie AG Br J Clin Pract Suppl; 1989 Jan; 65():18-23; discussion 23-5. PubMed ID: 2554949 [No Abstract] [Full Text] [Related]
11. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities. Peyrou V; Béguin S; Boneu B; Hemker HC Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588 [TBL] [Abstract][Full Text] [Related]
12. [Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin]. Hamann H Zentralbl Chir; 1999; 124(1):24-6. PubMed ID: 10091293 [TBL] [Abstract][Full Text] [Related]
13. Treatment of venous thromboembolism: unfractionated heparin or low molecular weight heparins? Agnelli G Haematologica; 1995; 80(2 Suppl):78-83. PubMed ID: 7628776 [No Abstract] [Full Text] [Related]
14. Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke. Turpie AG Acta Chir Scand Suppl; 1988; 543():85-6. PubMed ID: 2847462 [No Abstract] [Full Text] [Related]
15. [Current indications of low-molecular-weight heparins]. Vignes S; Meyer G; Marjanovic Z; Farge-Bancel D Ann Med Interne (Paris); 1997; 148(2):154-62. PubMed ID: 9238441 [TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparin for the prevention and treatment of venous thromboembolism. Raskob GE Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157 [TBL] [Abstract][Full Text] [Related]
17. Antithrombotic therapy with low molecular weight heparin in cancer patients. Petralia P; Kakkar AK Eur J Med Res; 2004 Mar; 9(3):119-24. PubMed ID: 15096321 [TBL] [Abstract][Full Text] [Related]
18. [Current status of low molecular weight heparin]. Maillet P Phlebologie; 1992; 45(2):179-83. PubMed ID: 1326773 [TBL] [Abstract][Full Text] [Related]
19. Review of clinical trials of low molecular weight heparins. Bergqvist D Eur J Surg; 1992 Feb; 158(2):67-78. PubMed ID: 1350218 [No Abstract] [Full Text] [Related]
20. [Low molecular weight heparins. Implications in anesthesia and resuscitation]. Llau JV; Hoyas L; Ezpeleta J; García-Polit J; Barberá M; Santes MJ Rev Esp Anestesiol Reanim; 1997 Feb; 44(2):70-8. PubMed ID: 9148359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]